Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

renal cell carcinoma (rcc), metastatic castration-resistant prostate cancer (mcrpc), urothelial carcinoma (uc), solid tumor, hepatocellular carcinoma (hcc), non-small cell lung cancer (nsclc), colorectal cancer (crc), head and neck squamous cell carcinoma (hnscc), clear cell renal cell carcinoma (ccrcc), non-clear cell renal cell carcinoma (nccrcc), drug-drug interaction (ddi), interventional